<DOC>
	<DOCNO>NCT01127958</DOCNO>
	<brief_summary>The main objective study determine whether PCI in-stent restenosis drug elute balloon angiographically non-inferior PCI drug elute stent 6 month follow .</brief_summary>
	<brief_title>DARE-trial : A Trial Studying Effect SeQuent Please Drug-eluting Balloon Compared Xience Prime Drug-eluting Stent Treatment Stenosis Earlier Implanted Stent .</brief_title>
	<detailed_description>Background study : Coronary in-stent restenosis commonly treat use drug elute stent ( DES ) . There , however , concern safety drug elute stent , particular respect delay healing , chronic inflammatory reaction , late late stent thrombosis . It unknown whether current treatment another layer stent may add risk stent thrombosis reoccurrence restenosis . Therefore , relatively new drug-eluting balloon may provide alternative treatment in-stent restenosis , avoid double stent layer . The expected advantage drug-eluting balloon stent ease access lesion , absence multiple stent layer , short necessity use dual antiplatelet therapy . Several study demonstrate safety efficacy Sequent Please drug-eluting balloon ( DEB ) . Whether drug elute balloon effective drug elute stent prevent re-restenosis know . Study design : The study design multi-center , randomize , prospective two-arm trial either PCI drug elute balloon drug elute stent in-stent restenosis . Blinded evaluation endpoint independent core laboratory . Study population : The study population consist 270 patient ( ≥ 18 year age ) indication PCI in-stent restenosis 135 randomise drug elute balloon 135 randomise drug elute stent . Individuals sign inform consent study measurement . Intervention : PCI drug-eluting stent , PCI drug-eluting balloon .</detailed_description>
	<criteria>Restenosis initially stented main vessel , include ostial , leave main bifurcation lesion well venous arterial graft Restenosis type stent ; drugeluting stent bare metal stent Restenosis must present &gt; 50 % instent &lt; 5 mm stent A reference diameter ≥ 2.0 4.0 millimeter visual estimation Amendable PCI treatment either SeQuent ® Please DEB Xience™ Prime DES Amendable dual antiplatelet treatment duration 1 year Patients must ≥ 18 year age Patients must able understand aim study , include risk , benefit treatment alternative Patients must agree undergo followup angiogram 6 month ( ± 1 month ) Patients must agree undergo clinical followup 30 day , 6 month , 1 , 2 , 3 , 4 , 5 year The impossibility arrange followup coronary angiography 6 month ( ± 1 month ) baseline procedure consider exclusion criterion study Patients meet inclusion criterion ; Life expectancy less one year Severe renal insufficiency ( glomerular filtration rate &lt; 30mL/min ) , exception patient renal dialysis STEMI Restenosis biodegradable stent Restenosis non CE mark stent Requirement PCI vessel expect next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>In-stent restenosis</keyword>
	<keyword>Minimal lumen diameter</keyword>
	<keyword>Drug elute balloon</keyword>
	<keyword>Drug elute stent</keyword>
</DOC>